The Harmonization of the Microbial Limits Tests - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Harmonization of the Microbial Limits Tests


Pharmaceutical Technology


The introduction of these three harmonized chapters is likely to require some revalidation of existing methodologies. Companies should put plans in place immediately for this work and show consistent progress toward this goal.

The National Formulary monograph requirements for the absence of specific organisms is a minimal requirement and should not be taken as proof that the product is suitable for sale from a microbiological perspective. Harmonized Chapter ‹1111› recommends the determination of the risk associated with "other organisms," which is in agreement with the FDA expectation for absence of "objectionable" organisms. The manufacturer is responsible for the quality and safety of the product marketed, and it is FDA's clear expectation (as described in CFR) that this will include a determination of the microbial safety (i.e., the "absence of objectionable microorganisms") from the product. These positions have been publicly stated for decades and should not come as a surprise. The harmonized microbial limits tests only address the "absence of specified microorganisms" and leave the determination of the "absence of objectionable microorganisms" in the capable hands of each company's appropriately educated and well-trained microbiology group.

Scott Sutton, PhD, is a consultant with emphasis on microbiology and GMP issues at Vectech Pharmaceutical Consultants, Inc., tel. 585.594.8273,
He also operates the PMFList, a microbiology e-mail list (http:// http://www.microbiol.org/pmflist.htm) and the PSDG e-mail list (pharmaceutical stability topics).

Submitted: Aug. 30, 2006. Accepted: Sept. 26, 2006.

Keywords: European Pharmacopoeia, Japanese Pharmacopoeia,limits, microbial testing, US Pharmacopeia,

References

1. USP Chapter ‹1196›, "Pharmacopeial Harmonization," US Pharmacopeia (USP) 29–National Formulary (NF) 24 (US Pharmacopeial Convention [USP], Rockville, MD, 2006), pp. 3031–3035.

2. USP, Chapter ‹61›, "Microbiological Examination Of Nonsterile Products: Microbial Enumeration Tests," Pharm Forum. 29 (5), 1714–1722 (2003).

3. USP, Chapter ‹62›, "Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms," Pharm Forum. 29 (5), 1722–1733 (2003).

4. USP, Chapter ‹1111›, "Microbiological Quality of Nonsterile Pharmaceutical Products," Pharm Forum. 29 (5), 1733–1735 (2003).

5. Chapter ‹61›, "Microbial Limits Tests," USP 29–NF 24 (US Pharmacopeial Convention, Rockville, MD, 2006), pp. 2503–2508.

6. Chapter ‹1111›, "Microbiological Attributes of Nonsterile Pharmaceutical Products," USP 29–NF 24 (USP, Rockville, MD, 2006), p. 2969.

7. European Directorate for the Quality of Medicines, http:// http://www.pheur.org/site/page_630.php?rubrique=446, accessed Oct. 23, 2006.

8. US Food and Drug Administration, Bacterial Analytical Manual Online, http:// http://www.cfsan.fda.gov/~ebam/bam-toc.html. The second appendix with tutorial on most probable number methods: http:// http://www.cfsan.fda.gov/~ebam/bam-a2.html, accessed Oct. 20, 2006.

9. Chapter ‹1227›, "Validation of Microbial Recovery from Pharmacopeial Articles," USP 29–NF 24 (USP, Rockville, MD, 2006), pp. 3053–3055.

10. USP, Chapter ‹1117›, "Microbiological Best Laboratory Practices," Pharm Forum. 30 (5), 1713–1721 (2004).

11. US Food and Drug Administration, "Guide to Inspections of Microbiological Pharmaceutical Quality Control Laboratories," http://www.fda.gov/ora/inspect_ref/igs/micro.html, accessed Oct. 20, 2006.

12. Chapter "Bacteriological Examination of Gelatin," USP XII (USP, Rockville, MD, 1942), pp. 556–559.

13. Chapter, "Microbial Limit Tests," USP XVIII (USP, Rockville, MD, 1970), p. 846.

14. J. Price, "Establishing Microbiological Specifications for Pharmaceuticals Not Required to Be Sterile," Pharm. Mfg. (April) 26–29 (1984).

15 . R.J. Kuhn et al., "Bacterial Contamination of Aerosol Solutions Used To Treat Cystic Fibrosis," Amer. J. Hosp. Pharm. 39 308–309 (1982).

16. L.A. Carson et al., "Morphological, Biochemical and Growth Characteristics of Pseudomonas cepacia from Distilled Water," Appl. Microbiol. 25 (3), 476–483 (1973).

17. S.G. Geftic et al., "Fourteen-Year Survival of Pseudomonas cepacia In a Salts Solution Preserved with Benzalkonium Chloride," Appl. Microbiol. 37 (3), 505–510 (1979).

18. R.L. Anderson et al., "Prolonged Survival of a Strain of Pseudomonas cepacia in a Commercially Manufactured Povidone-Iodine," Appl. Environ. Microbiol. 56 3598 (1990).

19. W.B.Hugo et al., "Factors Contributing to the Survival of a Strain of Pseudomonas cepacia In Chlorhexidine Solutions," Lett. Appl. Microbiol. 2, 37–42 (1982).

20. G.E. Borovian, "Pseudomonas cepacia: Growth In and Adaptability to Increased Preservative Concentrations," J. Soc. Cosmet. Chem. 34 197–203 (1983).

21. R.M.E. Richards et al., "Pseudomonas cepacia Resistance to Antibacterials," J. Pharm. Sci. 68 1436–1438 (1979).

22. USP, "Microbial Contamination of Sterile and Non-Sterile Articles, with Special Reference to Pseudomonas cepacia," Pharm. Forum. 8 (4), 2239 (1982).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here